Cost-effectiveness of Screening for Atrial Fibrillation Using Wearable Devices
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Importance: Undiagnosed atrial fibrillation (AF) is an important cause of stroke. Screening for AF using wrist-worn wearable devices may prevent strokes, but their cost-effectiveness is unknown. Objective: To evaluate the cost-effectiveness of contemporary AF screening strategies, particularly wrist-worn wearable devices. Design Setting and Participants: This economic evaluation used a microsimulation decision-analytic model and was conducted from September 8, 2020, to May 23, 2022, comprising 30 million simulated individuals with an age, sex, and comorbidity profile matching the US population aged 65 years or older. Interventions: Eight AF screening strategies, with 6 using wrist-worn wearable devices (watch or band photoplethysmography, with or without watch or band electrocardiography) and 2 using traditional modalities (ie, pulse palpation and 12-lead electrocardiogram) vs no screening. Main Outcomes and Measures: The primary outcome was the incremental cost-effectiveness ratio, defined as US dollars per quality-adjusted life-year (QALY). Secondary measures included rates of stroke and major bleeding. Results: In the base case analysis of this model, the mean (SD) age was 72.5 (7.5) years, and 50% of the individuals were women. All 6 screening strategies using wrist-worn wearable devices were estimated to be more effective than no screening (range of QALYs gained vs no screening, 226-957 per 100 000 individuals) and were associated with greater relative benefit than screening using traditional modalities (range of QALYs gained vs no screening, -116 to 93 per 100 000 individuals). Compared with no screening, screening using wrist-worn wearable devices was associated with a reduction in stroke incidence by 20 to 23 per 100 000 person-years but an increase in major bleeding by 20 to 44 per 100 000 person-years. The overall preferred strategy was wearable photoplethysmography, followed conditionally by wearable electrocardiography with patch monitor confirmation, which had an incremental cost-effectiveness ratio of $57 894 per QALY, meeting the acceptability threshold of $100 000 per QALY. The cost-effectiveness of screening was consistent across multiple scenarios, including strata of sex, screening at earlier ages (eg, ≥50 years), and with variation in the association of anticoagulation with risk of stroke in the setting of screening-detected AF. Conclusions and Relevance: This economic evaluation of AF screening using a microsimulation decision-analytic model suggests that screening using wearable devices is cost-effective compared with either no screening or AF screening using traditional methods.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879
Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62343-0 · Cited by 5,051
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Rivaroxaban with or without aspirin in stable cardiovascular disease
Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709118 · Cited by 2,438
Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold
Neumann, P. J., Cohen, J. T., & Weinstein, M. C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1405158 · Cited by 2,249
Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation
Perez, M. V., Mahaffey, K. W., Hedlin, H., Rumsfeld, J. S., Garcia, A., Ferris, T., Balasubramanian, V., Russo, A. M., Rajmane, A., Cheung, L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901183 · Cited by 1,917
Atrial Fibrillation: A Major Contributor to Stroke in the Elderly: The Framingham Study
Wolf, P. A. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370090041008 · Cited by 1,108
Marini, C., De Santis, F., Sacco, S., Russo, T., Olivieri, L., Totaro, R., & Carolei, A. (2005) · Stroke · doi:10.1161/01.str.0000166053.83476.4a · Cited by 949
Cited by
Applied body-fluid analysis by wearable devices
Brasier, N., Wang, J., Gao, W., Sempionatto, J. R., Dincer, C., Ates, H. C., Güder, F., Olenik, S., Schauwecker, I., Schaffarczyk, D., et al. (2024) · Nature · doi:10.1038/s41586-024-08249-4 · Cited by 298
Wearable Devices in Cardiovascular Medicine
Hughes, A., Shandhi, M. M. H., Master, H., Dunn, J., & Brittain, E. (2023) · Circulation Research · doi:10.1161/circresaha.122.322389 · Cited by 291
Dhingra, L. S., Aminorroaya, A., Oikonomou, E. K., Nargesi, A. A., Wilson, F. P., Krumholz, H. M., & Khera, R. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.16634 · Cited by 158
Artificial Intelligence–Enabled Prediction of Heart Failure Risk From Single-Lead Electrocardiograms
Dhingra, L. S., Aminorroaya, A., Pedroso, A. F., Khunte, A., Sangha, V., McIntyre, D., Chow, C. K., Asselbergs, F. W., Brant, L. C. C., Barreto, S. M., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0492 · Cited by 65
“67,68,71 This scalability and potential community health benefits necessitate prospective clinical and cost-effectiveness assessments for AI-based HF risk stratification.”
Enhanced Detection and Prompt Diagnosis of Atrial Fibrillation Using Apple Watch
van Steijn, N. J., Blommestijn, I. S., Blok, S., Pepplinkhuizen, S., Somsen, G. A., Knops, R. E., Breukel, L., Tijssen, J. G. P., Tulevski, I. I., Croon, P. M., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.032 · Cited by 21
Metadata
- Authors
- Chen, W., Khurshid, S., Singer, D. E., Atlas, S. J., Ashburner, J. M., Ellinor, P. T., McManus, D. D., Lubitz, S. A., & Chhatwal, J.
- Venue
- JAMA Health Forum
- Publisher
- American Medical Association (AMA)
- Published
- 2022-08-05
- Volume
- 3
- Issue
- 8
- Pages
- e222419
- ISSN
- 2689-0186 (ISSN-L)
- OpenAlex
- W4289933454
- Cited by
- 61
- References
- 23
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost-effectiveness of Screening for Atrial Fibrillation Using Wearable Devices. https://app.cochat.ai/papers/10.1001/jamahealthforum.2022.2419
- The paper
- Chen, W., Khurshid, S., Singer, D. E., Atlas, S. J., Ashburner, J. M., Ellinor, P. T., McManus, D. D., Lubitz, S. A., & Chhatwal, J. (2022). Cost-effectiveness of Screening for Atrial Fibrillation Using Wearable Devices. JAMA Health Forum. https://doi.org/10.1001/jamahealthforum.2022.2419
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.